Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
54.7M
-
Number of holders
-
86
-
Total 13F shares, excl. options
-
43.3M
-
Shares change
-
-10.6M
-
Total reported value, excl. options
-
$50.6M
-
Value change
-
-$154M
-
Put/Call ratio
-
0.31
-
Number of buys
-
53
-
Number of sells
-
-82
-
Price
-
$1.17
Significant Holders of Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) as of Q2 2024
163 filings reported holding MRNS - Marinus Pharmaceuticals, Inc. - Common Stock as of Q2 2024.
Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) has 86 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43.3M shares
of 54.7M outstanding shares and own 79.04% of the company stock.
Largest 10 shareholders include TANG CAPITAL MANAGEMENT LLC (4.8M shares), Sofinnova Investments, Inc. (4.15M shares), Woodline Partners LP (3.98M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (3.82M shares), FRANKLIN RESOURCES INC (3.49M shares), VANGUARD GROUP INC (2.8M shares), Bain Capital Life Sciences Investors, LLC (2.27M shares), Lion Point Capital, LP (2.11M shares), Bleichroeder LP (1.87M shares), and BlackRock Inc. (1.87M shares).
This table shows the top 86 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.